UI Pharmaceuticals (UIP), a strategic asset of the University of Iowa (UI) College of Pharmacy, has partnered with MimiVax to manufacture SurVaxM, a novel immunotherapeutic vaccine designed to treat glioblastoma, one of the most aggressive forms of brain cancer, for use in clinical trials.

“This collaboration combines MimiVax’s innovative research with UIP’s expertise in formulation development and sterile production, accelerating the path to potentially transformative therapies for patients,” said Ryan Moreno, director of manufacturing operations at UIP.

MimiVax reports that SurVaxM demonstrated safety and tolerability in both a Phase I trial with patients experiencing recurrent or progressive malignant glioma and a Phase II trial in newly diagnosed glioblastoma. The vaccine recently completed a Phase II trial at several leading cancer centers across the United States.

This move comes as UIP opens new, advanced manufacturing lines, positioning it to do even more.